Research field (1)：
Pharmaceuticals - health and biochemistry
Research keywords (1)：
Signal Transduction
Papers (63)：
Sato Hidenori, Ishii Kuniaki, Obara Yutaro. Structural Variants of Midnolin, a Genetic Risk Factor for Parkinson's Disease, in a Yamagata Cohort. Biological and Pharmaceutical Bulletin. 2023. 46. 3. 379-381
Kanno Hidenori, Naito Sei, Obara Yutaro, Ito Hiromi, Ichiyanagi Osamu, Narisawa Takafumi, Kato Tomoyuki, Nagaoka Akira, Tsuchiya Norihiko. Effect of Extracellular Signal-Regulated Protein Kinase 5 Inhibition in Clear Cell Renal Cell Carcinoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022. 23. 15
Sagehashi Naoki, Obara Yutaro, Maruyama Ohki, Nakagawa Tadashi, Hosoi Toru, Ishii Kuniaki. Insulin Enhances Gene Expression of Midnolin, a Novel Genetic Risk Factor for Parkinson's Disease, via Extracellular Signal-Regulated Kinase, Phosphoinositide 3-Kinase and Multiple Transcription Factors in SH-SY5Y Cells. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2022. 381. 2. 68-78
Nakagawasai Osamu, Takahashi Kohei, Miura Yuki, Nemoto Wataru, Obara Yutaro, Tan-No Koichi. ERK5 inhibitor BIX02189 attenuates methamphetamine-induced hyperactivity by modulating microglial activation in the striatum. JOURNAL OF PHARMACOLOGICAL SCIENCES. 2022. 148. 3. 326-330
Fumiaki Nasu, Yutaro Obara, Yosuke Okamoto, Hiroaki Yamaguchi, Kazuya Kurakami, Ikuo Norota, Kuniaki Ishii. Azelnidipine treatment reduces the expression of Cav1.2 protein. Life sciences. 2021. 269. 119043-119043
